Moderna said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can ...
Moderna had hoped its shot would be at least 49% effective at preventing CMV infections, substantially reducing the risk of ...
Moderna Inc. stopped its efforts to develop mRNA-1647 as a vaccine for preventing congenital cytomegalovirus infection, the most common infectious cause of birth defects in the U.S. The pivotal and ...
During the past few months, President Trump and his health secretary, Robert F. Kennedy, Jr., have made sweeping, thinly ...
The push for a label change came after President Donald Trump held a news conference last month in which he told pregnant ...
The 19th News on MSN
Her refusal to approve a dangerous drug changed medical history
As federal workers face mass layoffs and a government shutdown, Dr. Frances Oldham Kelsey's story is a reminder of what ...
The lesson is not to fear a conspiracy, but to keep refining our definitions, sharpening our science, and remembering that ...
One study found that agricultural workers had more than 35 times the risk of heat-related deaths than other workers. But ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
The National Institutes of Health has renewed its investment in the Delaware IDeA Network of Biomedical Research Excellence ...
Moderna said its cytomegalovirus (CMV) vaccine didn't meet the primary efficacy endpoint in a Phase 3 trial, and it is discontinuing the clinical development program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback